Physician profile
Richard A Newcomb
NPI 1902326143
$17,056.52
in general payments reported to CMS, 2019-2025
11 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.12 · 2023: $167 · 2024: $302 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $1,011 · Travel and Lodging: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,659.49 |
| Food and Beverage | $1,011.49 |
| Travel and Lodging | $366.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,901.25 | 2025 | |
| Sanofi US Services INC. | $5,272.00 | 2025 | |
| Abbvie INC. | $2,950.49 | 2025 | |
| Daiichi Sankyo INC. | $324.88 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $247.51 | 2023-2025 | Jakafi, Niktimvo |
| Sanofi-Aventis U.S. LLC | $145.54 | 2025 | |
| Sobi, INC | $100.48 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $42.00 | 2025 | |
| Gamida Cell INC. | $30.89 | 2025 | Omisirge |
| Genetix Biotherapeutics INC | $22.36 | 2025 | Lyfgenia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Newcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.